PT960105E - Compostos de benzofurazano que aumentam a actividade do receptor de ampa - Google Patents

Compostos de benzofurazano que aumentam a actividade do receptor de ampa

Info

Publication number
PT960105E
PT960105E PT98906358T PT98906358T PT960105E PT 960105 E PT960105 E PT 960105E PT 98906358 T PT98906358 T PT 98906358T PT 98906358 T PT98906358 T PT 98906358T PT 960105 E PT960105 E PT 960105E
Authority
PT
Portugal
Prior art keywords
compounds
benzofurazano
ampa receptor
receptor activity
receptors
Prior art date
Application number
PT98906358T
Other languages
English (en)
Inventor
Gary A Rogers
Christopher M Marrs
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT960105E publication Critical patent/PT960105E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
PT98906358T 1997-02-13 1998-02-13 Compostos de benzofurazano que aumentam a actividade do receptor de ampa PT960105E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
PT960105E true PT960105E (pt) 2004-09-30

Family

ID=25177504

Family Applications (2)

Application Number Title Priority Date Filing Date
PT98906358T PT960105E (pt) 1997-02-13 1998-02-13 Compostos de benzofurazano que aumentam a actividade do receptor de ampa
PT04075259T PT1428534E (pt) 1997-02-13 1998-02-13 Derivados de benzofurazano para aumentar as respostas sinapticas glutamatergicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT04075259T PT1428534E (pt) 1997-02-13 1998-02-13 Derivados de benzofurazano para aumentar as respostas sinapticas glutamatergicas

Country Status (24)

Country Link
US (3) US6110935A (pt)
EP (2) EP0960105B1 (pt)
JP (1) JP4446023B2 (pt)
KR (1) KR100544295B1 (pt)
CN (1) CN1085206C (pt)
AT (2) ATE326221T1 (pt)
AU (1) AU737802C (pt)
BR (1) BR9807333B1 (pt)
CA (1) CA2279319C (pt)
CZ (1) CZ299765B6 (pt)
DE (2) DE69823803T2 (pt)
DK (2) DK0960105T3 (pt)
ES (2) ES2221152T3 (pt)
GB (1) GB2325225B (pt)
HU (1) HUP0002303A3 (pt)
ID (1) ID22342A (pt)
IL (1) IL131200A (pt)
NO (1) NO318935B1 (pt)
NZ (1) NZ336980A (pt)
PL (1) PL199135B1 (pt)
PT (2) PT960105E (pt)
RU (1) RU2189984C2 (pt)
TR (1) TR199901941T2 (pt)
WO (1) WO1998035950A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (pt) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
WO2003053439A1 (en) * 2001-12-20 2003-07-03 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
NZ540468A (en) * 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
JP4829791B2 (ja) * 2003-05-23 2011-12-07 バジリア ファルマスーチカ アーゲー フラザノベンゾイミダゾール
US20050228019A1 (en) * 2004-01-26 2005-10-13 Cortex Pharmaceuticals, Inc. Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors
AU2007291848B2 (en) 2006-08-31 2012-01-12 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
NZ578293A (en) * 2007-01-03 2012-01-12 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
WO2008085505A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CA2685858C (en) 2007-05-17 2015-11-24 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
CN101896183B (zh) * 2007-08-10 2013-11-27 科泰克斯药品公司 用于增强谷氨酸能突触反应的二环酰胺
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
WO2010054336A2 (en) * 2008-11-10 2010-05-14 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
AU2010208646A1 (en) * 2009-02-02 2011-09-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
WO2012121971A2 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1Ｈ-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
AU2014277952A1 (en) 2013-06-13 2016-01-28 Veroscience Llc Compositions and methods for treating metabolic disorders
CN107286114B (zh) * 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP4374082B2 (ja) * 1992-07-24 2009-12-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ａｍｐａ受容体によって仲介されるシナプス応答性を高める薬物
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
JP2001512459A (ja) 2001-08-21
HUP0002303A2 (hu) 2001-04-28
NO318935B1 (no) 2005-05-30
TR199901941T2 (xx) 1999-12-21
RU2189984C2 (ru) 2002-09-27
AU737802C (en) 2005-05-12
EP1428534A1 (en) 2004-06-16
CN1085206C (zh) 2002-05-22
ID22342A (id) 1999-09-30
CZ299765B6 (cs) 2008-11-19
PL199135B1 (pl) 2008-08-29
WO1998035950A1 (en) 1998-08-20
IL131200A (en) 2005-06-19
CZ279599A3 (cs) 2000-01-12
PL335058A1 (en) 2000-03-27
DE69823803T2 (de) 2005-04-14
US6313115B1 (en) 2001-11-06
KR100544295B1 (ko) 2006-01-23
US6730677B2 (en) 2004-05-04
CN1247534A (zh) 2000-03-15
ATE326221T1 (de) 2006-06-15
BR9807333A (pt) 2000-04-18
EP1428534B1 (en) 2006-05-17
PT1428534E (pt) 2006-07-31
EP0960105B1 (en) 2004-05-12
DE69834590T2 (de) 2007-04-26
ES2264078T3 (es) 2006-12-16
KR20000071082A (ko) 2000-11-25
EP0960105A1 (en) 1999-12-01
US20020055508A1 (en) 2002-05-09
DE69823803D1 (de) 2004-06-17
DK0960105T3 (da) 2004-08-30
CA2279319A1 (en) 1998-08-20
GB9809221D0 (pt) 1998-07-01
GB2325225A8 (en) 1999-02-17
GB2325225B (en) 1999-03-03
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
IL131200A0 (en) 2001-01-28
JP4446023B2 (ja) 2010-04-07
NO993768D0 (no) 1999-08-04
ATE266649T1 (de) 2004-05-15
CA2279319C (en) 2008-08-05
US6110935A (en) 2000-08-29
AU737802B2 (en) 2001-08-30
ES2221152T3 (es) 2004-12-16
BR9807333B1 (pt) 2011-10-18
DK1428534T3 (da) 2006-06-12
GB2325225A (en) 1998-11-18
AU6159998A (en) 1998-09-08
HUP0002303A3 (en) 2002-09-30
DE69834590D1 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
PT960105E (pt) Compostos de benzofurazano que aumentam a actividade do receptor de ampa
DK0891365T3 (da) Benzoxaziner til forstærkning af synaptiske responser
PT839134E (pt) Benzoilpiperidinas/pirrolidinas para melhoramento da resposta sinaptica
DK1054673T3 (da) Benzoxazinforbindelser til forstærkelse af synaptisk reaktion
ES2060918T3 (es) Derivados de ciclopropilo que poseen actividad inhibidora lipoxigenasa.
ES2059301T3 (es) Utilizacion de inhibidores de la enzima convertidora de angiotensina para el tratamiento de la aterosclerosis, trombosis y de la enfermedad vascular periferica.
PT874843E (pt) 4-(1h-benzimidazol-2-il)¬1,4|diazepinos substituidos uteis para o tratamento de doencas alergicas
PT1067935E (pt) Acilbenzoxazinas para melhorar resposta (s) sinaptica (s)
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов
ES2169723T3 (es) Derivados de piridinio y su uso para determinar trastornos del tejido conectivo en seres humanos y animales.
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
NO180303C (no) Kondenserte diazepinoner, og midler som inneholder disse forbindelser
CA2249654A1 (en) Benzoxazines for enhancing synaptic response